©The Author(s) 2025.
World J Gastrointest Surg. Nov 27, 2025; 17(11): 109989
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.109989
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.109989
Table 4 Oncological outcomes
| Ref. | R0 resection rate | 1-year OS | 3-year OS | 5-year OS | Key oncological findings |
| Safiejko et al[6] | NR | 81.8% (RLR) vs 91.8% (LLR) | 47.7% (RLR) vs 65.9% (LLR) | NR | Trend favoring LLR (NS) |
| Machairas et al[7] | 100% (29/29) | NR | NR | 75.2% (single study) | All R0 resections |
| Mkabaah et al[9] | |||||
| RLR | 82.1% (202/246) | 100% (12/12) | 41.7% (5/12) | NR | No significant differences between approaches |
| LLR | 84.6% (2501/2957) | 93.0% (213/229) | 69.4% (159/229) | 53.1% (191/360) | |
| OLR | 87.7% (2277/2597) | 96.4% (321/333) | 69.3% (231/333) | 60.8% (477/785) | |
| Ho et al[12] | NR | NR | NR | NR | Mixed malignancies included |
| McGuirk et al[13] | 100% (28/28) | NR | NR | NR | Margin status reported for all cases1 |
- Citation: Ardila CM, Zuluaga-Gómez M, González-Arroyave D. Robotic liver surgery for metastatic disease: A review of safety, feasibility, and outcomes. World J Gastrointest Surg 2025; 17(11): 109989
- URL: https://www.wjgnet.com/1948-9366/full/v17/i11/109989.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i11.109989